Amoxicillin

Urinary Tract Infections, Sinusitis, Gonorrhea + 11 more

Treatment

2 FDA approvals

20 Active Studies for Amoxicillin

Treatment for

Urinary Tract Infections

What is Amoxicillin

Amoxicillin

The Generic name of this drug

Treatment Summary

Amoxicillin, also known as BRL-2333, is a type of penicillin antibiotic. It was first introduced in 1972 and was approved by the FDA in 1974. Amoxicillin works similarly to penicillin and ampicillin, but it tends to stay in the bloodstream for a longer period of time.

Amoxicillin

is the brand name

Amoxicillin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Amoxicillin

1978

1067

Approved as Treatment by the FDA

Amoxicillin, also called Amoxicillin, is approved by the FDA for 2 uses including Duodenal Ulcer and Duodenal ulcer caused by helicobacter pylori .

Duodenal Ulcer

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Clarithromycin

Duodenal ulcer caused by helicobacter pylori

Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Clarithromycin

Effectiveness

How Amoxicillin Affects Patients

Amoxicillin works by stopping bacteria from forming their cell walls, which keeps them from reproducing. It has a long lasting effect when taken twice a day. It is generally safe even when taken in higher doses. However, patients should be aware of potential risks such as anaphylaxis, C. difficile infections, and antibiotic resistance.

How Amoxicillin works in the body

Amoxicillin works by stopping certain proteins from helping bacteria build and repair their cell walls. Without these proteins, bacteria cannot properly build or repair the walls and eventually die.

When to interrupt dosage

The recommended measure of Amoxicillin is contingent upon the specified condition, such as Lower Respiratory Tract Infection (LRTI), Duodenal Ulcer and Stomach Ulcer. The amount of dosage differs, based on the administration approach (e.g. For suspension - Oral or Oral) as illustrated in the table below.

Condition

Dosage

Administration

ear, nose, and throat infections

, 500.0 mg, 875.0 mg, 200.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 600.0 mg/mL, 250.0 mg, 125.0 mg/mL, 250.0 mg/mL, 125.0 mg, 775.0 mg, 1000.0 mg, 25.0 mg/mL, 50.0 mg/mL, 600.0 mg, 437.5 mg, 2000.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Tablet, chewable, Tablet, chewable - Oral, Kit, Suspension - Oral, Capsule, Capsule - Oral, Suspension, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Powder, for solution, Powder, for solution - Oral, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Tablet, soluble, Tablet, soluble - Oral, Tablet, for suspension - Oral, Tablet, for suspension, Tablet, extended release - Oral, Tablet, extended release, Kit - Oral, Intravenous, Powder, for solution - Intravenous, Capsule, delayed release, Capsule, delayed release - Oral

Gonorrhea

Sinusitis

Bronchitis

Otitis

ABDIC protocol

Duodenal Ulcer

Bacterial Infections

Urinary Tract Infection (UTI)

Peptic Ulcer With H. Pylori Infection

Community Acquired Pneumonia (CAP)

Urinary Tract Infections

Helicobacter Pylori Infection

Warnings

Amoxicillin Contraindications

Condition

Risk Level

Notes

Liver Dysfunction

Do Not Combine

Pulse Frequency

Do Not Combine

Jaundice, Obstructive

Do Not Combine

Jaundice, Obstructive

Do Not Combine

Liver Dysfunction

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Amoxicillin may interact with Pulse Frequency

There are 20 known major drug interactions with Amoxicillin.

Common Amoxicillin Drug Interactions

Drug Name

Risk Level

Description

Vibrio cholerae CVD 103-HgR strain live antigen

Major

The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Amoxicillin.

Aclidinium

Minor

Amoxicillin may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Acrivastine

Minor

Amoxicillin may decrease the excretion rate of Acrivastine which could result in a higher serum level.

Albutrepenonacog alfa

Minor

Amoxicillin may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.

Allylestrenol

Minor

Amoxicillin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.

Amoxicillin Toxicity & Overdose Risk

Overdosing on phenytoin may cause blood in the urine, reduced urine output, abdominal pain, kidney failure, vomiting, diarrhea, rash, hyperactivity, and drowsiness. Treatment for phenytoin overdose includes supportive care and may involve inducing vomiting or dialysis.

Amoxicillin Novel Uses: Which Conditions Have a Clinical Trial Featuring Amoxicillin?

60 active trials are currently being conducted to investigate the potential of Amoxicillin in alleviating Urinary Tract Infections, ENT infections and Bacterial Infections.

Condition

Clinical Trials

Trial Phases

Bacterial Infections

0 Actively Recruiting

Urinary Tract Infections

0 Actively Recruiting

Duodenal Ulcer

0 Actively Recruiting

Bronchitis

2 Actively Recruiting

Not Applicable

ABDIC protocol

0 Actively Recruiting

ear, nose, and throat infections

0 Actively Recruiting

Community Acquired Pneumonia (CAP)

5 Actively Recruiting

Not Applicable, Phase 1, Phase 3

Sinusitis

2 Actively Recruiting

Not Applicable

Helicobacter Pylori Infection

2 Actively Recruiting

Not Applicable, Phase 4

Peptic Ulcer With H. Pylori Infection

0 Actively Recruiting

Urinary Tract Infections

7 Actively Recruiting

Not Applicable, Phase 4

Gonorrhea

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Otitis

3 Actively Recruiting

Not Applicable

Patient Q&A Section about amoxicillin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is amoxicillin used for?

"Amoxicillin is an antibiotic that belongs to the group of penicillins. It is used to treat bacterial infections like chest infections, pneumonia, and dental abscesses. It can also be used in combination with other antibiotics and medications to treat stomach ulcers."

Answered by AI

What is the most common side effect of amoxicillin?

"Side effects of amoxicillin are typically mild and can include gastrointestinal issues such as an upset stomach and diarrhea, as well as a headache, rash, abnormal taste, and vaginal yeast infection. Some less common side effects that have been recorded include allergic reactions, breathing problems, and seizures."

Answered by AI

How many days should I take amoxicillin 500mg?

"The text is saying that amoxicillin is given for 5-10 days or until the infection clears. People who have recurrent ear infections are more likely to get amoxicillin/clavulanate because bacteria can become resistant to amoxicillin."

Answered by AI

What infections does amoxicillin treat?

"Amoxicillin is an antibiotic that is used to fight off infection by bacteria. Amoxicillin is commonly used to treat infections in the ear, nose, throat, skin, or urinary tract. It is also used to treat bronchitis and pneumonia."

Answered by AI

Clinical Trials for Amoxicillin

Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17

All Sexes

Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4

Waitlist Available

New This Month

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+

All Sexes

Houston, TX

Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. Hypothesis: patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.

Waitlist Available

Has No Placebo

Baylor College of Medicine

Larissa Grigoryan, MD, PhD